Compare Ginkgo Bioworks Holdings Inc (DNA) vs e l f Beauty Inc (ELF) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.

The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.

ELF Beauty trades at $105.96, up 0.89% today, showing strong momentum with three consecutive earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward trends, though RSI levels suggest potential overbought conditions. Fundamentally, the company maintains robust revenue growth ($1.31B in 2025) and expanding international presence through recent Sephora partnerships in Europe and Brazil. Recent news highlights innovative marketing strategies including music album releases and brand expansion initiatives.

Investment outlook remains positive with analyst consensus leaning bullish (48% buy ratings) despite premium valuation metrics. Key opportunities include international expansion and market share gains, while risks center on elevated P/E ratio (108.12) and competitive pressures in the beauty sector. The $95.91 consensus price target suggests modest downside from current levels, requiring careful risk management for new positions.